NasdaqGM:HROWPharmaceuticals
A Fresh Look at Harrow (HROW) Valuation Following $250M Debt Refinancing and Balance Sheet Moves
If you’ve been eyeing Harrow (HROW) recently, there’s a fresh reason for investors to give this stock a closer look. The company just priced a $250 million private offering of senior unsecured notes due 2030 at 8.625%, with plans to use the proceeds to reduce its outstanding debt. Harrow will be repaying its Oaktree facility in full, redeeming nearly $115 million of senior notes set to mature over the next two years, and using any remaining capital for general business needs. The mechanics...